Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Clin Oncol
Autors principals: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2021
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://ncbi.nlm.nih.gov/pubmed/33282288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2175
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars